JS Link

JS Link Liabilities

The The Liabilities of JS Link (127120.KQ) as of Oct 27, 2026 is 54.44 B KRW. In the previous year, The Liabilities was 29.36 B KRW — a change of 85.46% (higher).

Liabilities

54.44 BKRW

YoY

85.46%

Last updated:

In 2025, JS Link's total liabilities amounted to 54.44 B KRW, a 85.46% difference from the 29.36 B KRW total liabilities in the previous year.

The JS Link Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
15.46 B KRW
Jan 1, 2019
16.24 B KRW
Jan 1, 2020
13.84 B KRW
Jan 1, 2021
8.25 B KRW
Jan 1, 2022
15.62 B KRW
Jan 1, 2023
12.48 B KRW
Jan 1, 2024
29.36 B KRW
Jan 1, 2025
54.44 B KRW
The JS Link Liabilities history
YEARLiabilitiesYoY
54.44 BKRW+85.46%
29.36 BKRW+135.23%
12.48 BKRW-20.09%
15.62 BKRW+89.40%
8.25 BKRW-40.42%
13.84 BKRW-14.77%
16.24 BKRW+5.02%
15.46 BKRW+996.65%
1.41 BKRW-94.14%
24.04 BKRW+11.69%
21.53 BKRW+68.92%
12.74 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

JS Link Stock analysis

What does JS Link do? DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description. JS Link is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing JS Link's Liabilities

JS Link's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating JS Link's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing JS Link's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

JS Link's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in JS Link’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about JS Link stock

The Liabilities of JS Link is 54.44 B KRW in 2025.

The Liabilities of JS Link changed from 29.36 B KRW to 54.44 B KRW, representing a 85.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities JS Link since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's JS Link historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — JS Link

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — JS Link